TISIDB

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Note=Hypophosphorylated form is mainly found in the cytoplasm, while the hyperphosphorylated and active form is nuclear.
Domain	PF04997 RNA polymerase Rpb1 PF00623 RNA polymerase Rpb1 PF04983 RNA polymerase Rpb1 PF05000 RNA polymerase Rpb1 PF04998 RNA polymerase Rpb1 PF04992 RNA polymerase Rpb1 PF04990 RNA polymerase Rpb1 PF05001 RNA polymerase Rpb1 C-terminal repeat
Function	DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Regulation of gene expression levels depends on the balance between methylation and acetylation levels of tha CTD-lysines (By similarity). Initiation or early elongation steps of transcription of growth-factors-induced immediate early genes are regulated by the acetylation status of the CTD (PubMed:24207025). Methylation and dimethylation have a repressive effect on target genes expression (By similarity). ; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicate and transcriptase for the viral RNA circular genome.

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0001172 transcription, RNA-templated GO:0006283 transcription-coupled nucleotide-excision repair GO:0006289 nucleotide-excision repair GO:0006352 DNA-templated transcription, initiation GO:0006353 DNA-templated transcription, termination GO:0006354 DNA-templated transcription, elongation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0006368 transcription elongation from RNA polymerase II promoter GO:0006370 7-methylguanosine mRNA capping GO:0006397 mRNA processing GO:0008380 RNA splicing GO:0008543 fibroblast growth factor receptor signaling pathway GO:0009301 snRNA transcription GO:0009452 7-methylguanosine RNA capping GO:0016073 snRNA metabolic process GO:0016458 gene silencing GO:0019058 viral life cycle GO:0019080 viral gene expression GO:0019083 viral transcription GO:0019827 stem cell population maintenance GO:0031047 gene silencing by RNA GO:0033120 positive regulation of RNA splicing GO:0035019 somatic stem cell population maintenance GO:0036260 RNA capping GO:0042795 snRNA transcription from RNA polymerase II promoter GO:0043484 regulation of RNA splicing GO:0043900 regulation of multi-organism process GO:0043902 positive regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044033 multi-organism metabolic process GO:0044344 cellular response to fibroblast growth factor stimulus GO:0046782 regulation of viral transcription GO:0048524 positive regulation of viral process GO:0050434 positive regulation of viral transcription GO:0050792 regulation of viral process GO:0071774 response to fibroblast growth factor GO:0098727 maintenance of cell number GO:0098781 ncRNA transcription GO:1903900 regulation of viral life cycle GO:1903902 positive regulation of viral life cycle
Molecular Function	GO:0001055 RNA polymerase II activity GO:0003899 DNA-directed RNA polymerase activity GO:0003968 RNA-directed RNA polymerase activity GO:0016779 nucleotidyltransferase activity GO:0031625 ubiquitin protein ligase binding GO:0034062 RNA polymerase activity GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:0000428 DNA-directed RNA polymerase complex GO:0000974 Prp19 complex GO:0005665 DNA-directed RNA polymerase II, core complex GO:0016591 DNA-directed RNA polymerase II, holoenzyme GO:0030880 RNA polymerase complex GO:0055029 nuclear DNA-directed RNA polymerase complex GO:0061695 transferase complex, transferring phosphorus-containing groups

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03020 RNA polymerase hsa00230 Purine metabolism hsa00240 Pyrimidine metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat R-HSA-5619507: Activation of HOX genes during differentiation R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis R-HSA-73894: DNA Repair R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-6782135: Dual incision in TC-NER R-HSA-112387: Elongation arrest and recovery R-HSA-6803529: FGFR2 alternative splicing R-HSA-1839126: FGFR2 mutant receptor activation R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat R-HSA-112382: Formation of RNA Pol II elongation complex R-HSA-6781823: Formation of TC-NER Pre-Incision Complex R-HSA-113418: Formation of the Early Elongation Complex R-HSA-167158: Formation of the HIV-1 Early Elongation Complex R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER R-HSA-74160: Gene Expression R-HSA-211000: Gene Silencing by RNA R-HSA-212436: Generic Transcription Pathway R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-167169: HIV Transcription Elongation R-HSA-167161: HIV Transcription Initiation R-HSA-167287: HIV elongation arrest and recovery R-HSA-5663205: Infectious disease R-HSA-168254: Influenza Infection R-HSA-168255: Influenza Life Cycle R-HSA-168273: Influenza Viral RNA Transcription and Replication R-HSA-162599: Late Phase of HIV Life Cycle R-HSA-203927: MicroRNA (miRNA) biogenesis R-HSA-5696398: Nucleotide Excision Repair R-HSA-5601884: PIWI-interacting RNA (piRNA) biogenesis R-HSA-167290: Pausing and recovery of HIV elongation R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection R-HSA-167162: RNA Polymerase II HIV Promoter Escape R-HSA-674695: RNA Polymerase II Pre-transcription Events R-HSA-73776: RNA Polymerase II Promoter Escape R-HSA-73857: RNA Polymerase II Transcription R-HSA-75955: RNA Polymerase II Transcription Elongation R-HSA-75953: RNA Polymerase II Transcription Initiation R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening R-HSA-6807505: RNA polymerase II transcribes snRNA genes R-HSA-162582: Signal Transduction R-HSA-190236: Signaling by FGFR R-HSA-1226099: Signaling by FGFR in disease R-HSA-5654738: Signaling by FGFR2 R-HSA-8851708: Signaling by FGFR2 IIIa TM R-HSA-5655253: Signaling by FGFR2 in disease R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes R-HSA-167243: Tat-mediated HIV elongation arrest and recovery R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript R-HSA-167172: Transcription of the HIV genome R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER) R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-5578749: Transcriptional regulation by small RNAs R-HSA-452723: Transcriptional regulation of pluripotent stem cells R-HSA-168325: Viral Messenger RNA Synthesis R-HSA-72086: mRNA Capping R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway R-HSA-72165: mRNA Splicing - Minor Pathway

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03020 RNA polymerase
hsa00230 Purine metabolism
hsa00240 Pyrimidine metabolism
hsa01100 Metabolic pathways

Reactome

R-HSA-167242: Abortive elongation of HIV-1 transcript in the absence of Tat
R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-73894: DNA Repair
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-6782135: Dual incision in TC-NER
R-HSA-112387: Elongation arrest and recovery
R-HSA-6803529: FGFR2 alternative splicing
R-HSA-1839126: FGFR2 mutant receptor activation
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-6781823: Formation of TC-NER Pre-Incision Complex
R-HSA-113418: Formation of the Early Elongation Complex
R-HSA-167158: Formation of the HIV-1 Early Elongation Complex
R-HSA-6782210: Gap-filling DNA repair synthesis and ligation in TC-NER
R-HSA-74160: Gene Expression
R-HSA-211000: Gene Silencing by RNA
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167161: HIV Transcription Initiation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-168273: Influenza Viral RNA Transcription and Replication
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-203927: MicroRNA (miRNA) biogenesis
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-5601884: PIWI-interacting RNA (piRNA) biogenesis
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA
R-HSA-77075: RNA Pol II CTD phosphorylation and interaction with CE
R-HSA-167160: RNA Pol II CTD phosphorylation and interaction with CE during HIV infection
R-HSA-167162: RNA Polymerase II HIV Promoter Escape
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73776: RNA Polymerase II Promoter Escape
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-75953: RNA Polymerase II Transcription Initiation
R-HSA-76042: RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-73779: RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-162582: Signal Transduction
R-HSA-190236: Signaling by FGFR
R-HSA-1226099: Signaling by FGFR in disease
R-HSA-5654738: Signaling by FGFR2
R-HSA-8851708: Signaling by FGFR2 IIIa TM
R-HSA-5655253: Signaling by FGFR2 in disease
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-5578749: Transcriptional regulation by small RNAs
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
R-HSA-168325: Viral Messenger RNA Synthesis
R-HSA-72086: mRNA Capping
R-HSA-72172: mRNA Splicing
R-HSA-72163: mRNA Splicing - Major Pathway
R-HSA-72165: mRNA Splicing - Minor Pathway

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between POLR2A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of POLR2A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of POLR2A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.149	0.631
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.085	0.97
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.329	0.83
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.189	0.437
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.417	0.888
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.098	0.979
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.372	0.414
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.431	0.821
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.288	0.893
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.674	0.655
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.373	0.521
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.099	0.179

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of POLR2A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	35.7	0	35.7	0.0118
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	40	0	40	0.497
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	5.5	-1.8	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	6.8	-3.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POLR2A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POLR2A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POLR2A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POLR2A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of POLR2A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between POLR2A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	POLR2A
Name	polymerase (RNA) II (DNA directed) polypeptide A, 220kDa
Aliases	POLRA; RPB1; DNA-directed RNA polymerase II largest subunit, RNA polymerase II 220 kd subunit; RNA polymeras ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting POLR2A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse POLR2A